echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Betta Pharmaceuticals submits a marketing application for a new generation of multi-targeted kinase inhibitors

    Betta Pharmaceuticals submits a marketing application for a new generation of multi-targeted kinase inhibitors

    • Last Update: 2022-02-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    TextPharmaceutical Guanlan

    On January 11, the official website of the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of the People's Republic of China announced that Betta Pharmaceuticals submitted a marketing application for a class 1 new drug, voronib tablets, and was accepted


    Screenshot source: CDE official website

    According to the public information of Betta Pharmaceuticals, voronib has anti-angiogenic efficacy against multiple targets such as VEGFR, PDGFR, c-Kit, Flt-3, CSF1R, etc.


    Currently, the product is undergoing clinical trials in patients with end-stage renal disease and chronic age-related macular degeneration


    ▲Voronibu research and development progress (screenshot source: Betta Pharmaceuticals official website)

    At the 2021 American Society of Clinical Oncology (ASCO) annual meeting, Betta Pharmaceuticals announced the results of the CONCEPT study


    The results of the study showed that the progression-free survival (PFS) of the voronib + everolimus combination therapy group was longer than that of the everolimus single-agent group (median PFS, 10.


    In terms of safety, there were 132, 127 and 131 treatment-related adverse events (TRAEs) in the three groups of patients, respectively


    ▲CONCEPT research results (Image source: Reference [2])

    Betta Pharmaceuticals stated in a press release that the CONCEPT study is the first Phase 3 study of mTOR and VEGF-targeted drugs in second-line therapy


    This time Betta Pharmaceuticals has submitted a new drug listing application for voronib in China, which means that the product has entered the stage of listing application


    References:

    [1] Center for Drug Evaluation, National Medical Products Administration of China.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.